Life Sciences

The City of Worcester has moved assertively to ensure it is getting a fair deal with developers, placing demands on businesses without reversing Worcester's development-friendly reputation.

Massachusetts was chosen to host the National Institutes of Health agency's Investor Catalyst Hub, meant to help ARPA-H programs navigate the complexities of the business and regulatory landscape and provide resources to help bring ideas to market, according to the governor's office.

Webster developer Galaxy Life Sciences expects to expand a 90,000-square-foot biomanufacturing facility under construction at The Reactory biomanufacturing campus in Worcester to 246,000 square feet, pending approval from the City of Worcester.

Massachusetts Biomedical Initiatives in Worcester, a life science incubator, has been selected by the U.S. Small Business Administration as a stage two winner of its 2023 Growth Accelerator Fund Competition.

Rentschler Biopharma hired Tom Roberts as its first president of Milford-based U.S. operations, which is undergoing an historic expansion.

Marlborough-based medical technology giant Boston Scientific has agreed to acquire Relievant Medsystems, which has developed a proprietary technology to treat lower-back pain.

Framingham-based Alzheon, a clinical stage biopharmaceutical research and development firm, on Wednesday reported statistically significant results in brain preservation from a phase two trial of an early Alzheimer's disease drug.

Natick-based cancer detection firm Mercy BioAnalytics has added two executive positions to its roster ahead of commercialization plans for its product.

The Worcester incubator received a $375,000 grant from one of its successful graduate companies toward MBI’s $6-million goal to build out a biomanufacturing center.

Arch Therapeutics, a Framingham-based company specializing in wound care and biosurgical products, raised $2.6 million in bridge funding ahead of an intended uplisting of company stock.